Recombinant Chromobacterium violaceum Aspartate carbamoyltransferase (pyrB)

Shipped with Ice Packs
In Stock

Product Specs

Form
Lyophilized powder
Note: While we prioritize shipping the format currently in stock, please specify your format preference in order notes for customized fulfillment.
Lead Time
Delivery times vary depending on the purchase method and location. Please contact your local distributor for precise delivery estimates.
Note: Standard shipping includes blue ice packs. Dry ice shipping requires advance notification and incurs additional charges.
Notes
Avoid repeated freeze-thaw cycles. Store working aliquots at 4°C for up to one week.
Reconstitution
Centrifuge the vial briefly before opening to consolidate the contents. Reconstitute the protein in sterile, deionized water to a concentration of 0.1-1.0 mg/mL. For long-term storage, we recommend adding 5-50% glycerol (final concentration) and aliquoting at -20°C/-80°C. Our standard glycerol concentration is 50%, which can serve as a reference.
Shelf Life
Shelf life depends on various factors including storage conditions, buffer composition, temperature, and the protein's inherent stability. Generally, liquid formulations have a 6-month shelf life at -20°C/-80°C, while lyophilized forms have a 12-month shelf life at -20°C/-80°C.
Storage Condition
Upon receipt, store at -20°C/-80°C. Aliquot for multiple uses to prevent repeated freeze-thaw cycles.
Tag Info
The tag type is determined during manufacturing.
The tag type is determined during production. If a specific tag type is required, please inform us, and we will prioritize its development.
Synonyms
pyrB; CV_0369; Aspartate carbamoyltransferase; EC 2.1.3.2; Aspartate transcarbamylase; ATCase
Buffer Before Lyophilization
Tris/PBS-based buffer, 6% Trehalose.
Datasheet
Please contact us to get it.
Expression Region
1-302
Protein Length
full length protein
Purity
>85% (SDS-PAGE)
Species
Chromobacterium violaceum (strain ATCC 12472 / DSM 30191 / JCM 1249 / NBRC 12614 / NCIMB 9131 / NCTC 9757)
Target Names
pyrB
Target Protein Sequence
MYRKHIISIP DFSREELELV VDTAARLKQS PRGDLLQDKL VASCFFEPST RTRLSFETAV QRLGGNIIGF ADGGNTSAKK GETLADSIKI ISSYTDAVVM RHPKEGAARL ASEFSAVPVI NGGDGSNQHP TQTLLDLFSI RETQGRLDGL TVAFAGDLKY GRTVHSLAQA LSLFGARFYF VSPEVLAMPD YICEELDEKG ISYTVADSLE AVIPEVDVLY MTRVQRERFD EAEFRKIQGQ YALRADMLKH ARPGMKVLHP LPRVDEIAVD VDATPHAYYF EQAKNGVYAR QALLSLVLNE TV
Uniprot No.

Q&A

Research Applications and Broader Implications

  • How might understanding C. violaceum ATCase contribute to addressing the pathogenicity of this organism?

    C. violaceum is an opportunistic pathogen that can cause serious infections with high mortality rates (>50%) in humans, particularly following exposure to soil or water in tropical and subtropical regions . Understanding its ATCase may contribute to addressing pathogenicity in several ways:

    1. Metabolic vulnerability:

      • As a key enzyme in pyrimidine biosynthesis, ATCase represents a potential drug target

      • Pyrimidine metabolism is essential for bacterial replication and virulence

    2. Comparative analysis with host enzymes:

      • Structural and functional differences between bacterial and human ATCase can be exploited for selective inhibition

      • This approach could lead to development of targeted antimicrobials with minimal host toxicity

    3. Gene regulation studies:

      • Understanding the regulation of the pyrBI operon may reveal how C. violaceum adapts to host environments

      • The operon's expression pattern during infection could inform therapeutic strategies

    4. Connection to virulence factors:

      • Potential links between nucleotide metabolism and expression of virulence factors like the violacein pigment

      • Investigation of metabolic adaptations during infection

    5. Experimental approaches:

      • Gene knockout or knockdown studies to assess virulence in animal models

      • Transcriptomic analysis under infection-mimicking conditions

      • Metabolomic profiling to identify pyrimidine-related metabolites during infection

    Given the increasing reports of antibiotic-resistant C. violaceum infections , novel targets like ATCase may become increasingly important for developing alternative therapeutic strategies.

  • What role might C. violaceum ATCase play in the bacterium's environmental adaptation?

    C. violaceum is well-adapted to tropical and subtropical soil and water environments , and its ATCase may contribute to this ecological adaptation:

    1. Temperature adaptation:

      • Similar to psychrophilic Vibrio ATCase, C. violaceum ATCase may have evolved specific structural features for function in its preferred temperature range

      • Research methodology should include comparative thermostability studies with ATCases from bacteria adapted to different temperature ranges

    2. Metabolic flexibility:

      • The regulation of pyrB may be tuned to allow rapid adaptation to changing environmental conditions

      • Experimental approaches should include expression studies under various environmental stresses

    3. Resource allocation:

      • Efficient pyrimidine biosynthesis may contribute to C. violaceum's competitive success in nutrient-limited environments

      • Metabolic flux analysis would be an appropriate methodology to study this aspect

    4. Interaction with the violacein pigment pathway:

      • The distinctive purple pigment (violacein) of C. violaceum has antibiotic properties

      • Research into potential metabolic connections between pyrimidine biosynthesis and secondary metabolite production

    5. Biofilm formation:

      • Nucleotide metabolism may influence biofilm development, which is important for environmental persistence

      • Experimental approaches should include analysis of pyrB expression in planktonic versus biofilm states

    Understanding these adaptations could provide insights into bacterial evolution and potentially inform bioremediation or biotechnology applications utilizing C. violaceum in its native environments.

  • How can engineered variants of C. violaceum pyrB be utilized as model systems for understanding allosteric regulation in enzymes?

    Engineered variants of C. violaceum pyrB can serve as valuable model systems for studying allosteric regulation through systematic methodological approaches:

    1. Chimeric enzyme construction:

      • Creation of hybrid ATCases combining regulatory domains from different species

      • Swapping allosteric binding sites between C. violaceum ATCase and well-characterized systems like E. coli

      • Methodological considerations include careful domain boundary selection and structural stability validation

    2. Regulatory circuit engineering:

      • Introduction of non-native allosteric control mechanisms

      • Creating synthetic regulatory networks incorporating modified ATCase variants

      • Experimental design should include quantitative response measurements to various effectors

    3. Structural biology approaches:

      • Crystallization of engineered variants in different allosteric states

      • Comparison with wild-type structures to understand conformational changes

      • Cryo-EM for capturing dynamic transitions between states

    4. Computational modeling validation:

      • Using engineered variants with defined properties to test and refine computational models of allostery

      • Molecular dynamics simulations to predict and verify engineered behaviors

    5. Applications in synthetic biology:

      • Development of biosensors based on allosteric properties

      • Creation of switchable enzyme systems for biotechnology applications

      • Experimental design should include proof-of-concept demonstrations in relevant contexts

    The distinctive properties of C. violaceum ATCase, potentially different from the well-studied E. coli system , make it particularly valuable for comparative studies of allosteric mechanisms in nature and how they can be manipulated for research and application purposes.

Technical Challenges and Troubleshooting

  • What are common challenges in expressing and purifying active recombinant C. violaceum pyrB, and how can they be addressed?

    Researchers working with recombinant C. violaceum pyrB may encounter several challenges:

    ChallengePotential CausesMethodological Solutions
    Low expression yieldCodon bias, toxicity to host, mRNA secondary structureCodon optimization, use of specialized expression strains, alternative promoters, lower induction temperature (16-25°C)
    Insoluble protein/inclusion bodiesImproper folding, hydrophobic interactionsCo-expression with chaperones, fusion with solubility tags (MBP, SUMO), reduced induction temperature, inclusion of solubilizing agents (1-3% sarkosyl)
    Loss of activity during purificationOxidation of critical residues, dissociation of quaternary structureInclude reducing agents (5-10 mM β-mercaptoethanol, DTT), optimize buffer composition to maintain quaternary structure
    Heterogeneous quaternary structureImproper assembly, partial proteolysisSize exclusion chromatography, addition of stabilizing ligands during purification, protease inhibitor cocktails
    Inconsistent activity measurementsBatch-to-batch variation, instability of substratesStandardized activity assays, internal controls, careful substrate preparation and storage

    Specific methodological recommendations:

    1. For expression: Compare yeast , E. coli , and baculovirus systems to determine optimal host

    2. For protein solubility: If inclusion bodies form, attempt refolding with a gradient of denaturant (e.g., urea) removal through dialysis

    3. For maintaining quaternary structure: Include physiological concentrations of substrates or substrate analogs during purification

    4. For activity preservation: Determine optimal storage conditions through stability studies (buffer composition, pH, temperature)

    5. For quality control: Implement routine SEC-MALS analysis to verify quaternary structure integrity

  • How can researchers effectively design experiments to investigate the thermal stability of C. violaceum ATCase compared to homologs from other bacteria?

    To characterize and compare thermal stability profiles of C. violaceum ATCase with homologs, researchers should implement a systematic experimental design:

    1. Thermal shift assays:

      • Differential scanning fluorimetry using SYPRO Orange or similar dyes

      • Generate complete melting curves (20-95°C) at different pH values and buffer conditions

      • Include natural ligands and allosteric effectors to assess their stabilizing effects

      • Compare melting temperatures (Tm) and transition cooperativity

    2. Activity-based thermal profiling:

      • Measure residual activity after pre-incubation at various temperatures

      • Determine T50 (temperature at which 50% activity is lost)

      • Assess thermal inactivation kinetics at selected temperatures

      • Compare activation energies for thermal inactivation

    3. Structural studies:

      • Circular dichroism spectroscopy to monitor secondary structure changes with temperature

      • Intrinsic fluorescence to track tertiary structure alterations

      • Small-angle X-ray scattering to assess quaternary structure stability

    4. Comparative framework:

      • Include ATCases from bacteria adapted to different thermal niches:

        • Psychrophilic (e.g., Vibrio)

        • Mesophilic (e.g., E. coli)

        • Thermophilic (e.g., Thermus species)

      • Analyze sequence determinants of observed stability differences

    5. Data analysis approaches:

      • Fit appropriate models to thermal denaturation curves

      • Perform statistical comparisons of stability parameters

      • Correlate stability features with amino acid composition and structural elements

    This methodological framework would provide comprehensive insights into how C. violaceum ATCase has evolved thermal properties suited to its environmental niche, particularly in comparison to the psychrophilic Vibrio ATCase described in the literature .

  • What experimental approaches can effectively elucidate the substrate specificity of C. violaceum pyrB compared to other bacterial ATCases?

    A comprehensive investigation of substrate specificity requires multiple complementary approaches:

    1. Kinetic characterization with substrate analogs:

      • Systematically modify the aspartate substrate (e.g., β-methyl-aspartate, homoserine)

      • Test alternative carbamoyl donors to carbamoyl phosphate

      • Determine full kinetic parameters (Km, kcat, kcat/Km) for each substrate variant

      • Compare specificity constants (kcat/Km) to quantify preference

    2. Binding studies:

      • Isothermal titration calorimetry (ITC) to measure binding thermodynamics

      • Surface plasmon resonance (SPR) for binding kinetics

      • Fluorescence-based assays for high-throughput screening of substrate analogs

    3. Structural biology approaches:

      • Co-crystallization with substrate analogs or transition state mimics

      • Structure determination of enzyme-substrate complexes

      • Molecular docking to predict binding modes of untested substrates

    4. Mutagenesis of active site residues:

      • Identify active site residues through sequence alignment and structural models

      • Create systematic mutations to alter substrate pocket geometry

      • Assess changes in specificity to identify key determinants

    5. Comparative analysis:

      • Parallel characterization of ATCases from diverse bacteria (E. coli, Vibrio, thermophiles)

      • Correlation of specificity differences with active site variations

      • Phylogenetic analysis of specificity evolution

    Implementing this methodological framework would provide insights into whether C. violaceum ATCase has evolved unique substrate preferences related to its ecological niche or pathogenicity, and how these compare to the properties of other bacterial ATCases like the E. coli enzyme that has been extensively characterized.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.